This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene (CNC) Divests Circle Health Group, Optimizes Portfolio
by Zacks Equity Research
Centene (CNC) announces the sale of Circle Health Group to PureHealth in a bid to dispose of non-core assets and grow its core Managed Care business.
Humana (HUM) to Bring Enhanced Kidney Care to MA Members
by Zacks Equity Research
Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.
UnitedHealth (UNH) Wins Medicaid Deal to Serve New Mexicans
by Zacks Equity Research
UnitedHealth (UNH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.
Why Prudent Investors Are Snapping Up Ensign (ENSG) Stock Now
by Zacks Equity Research
Ensign (ENSG) expects to witness strong acquisition opportunities in the fall of this year.
Why Ensign Group (ENSG) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Encompass Health's (EHC) Q2 Earnings Beat, '23 EPS View Raised
by Zacks Equity Research
Encompass Health's (EHC) Q2 results reflect a growing patient base and improved net patient revenue per discharge. Management anticipates 2023 adjusted EPS within $3.31-$3.53, up from the earlier view of $2.94-$3.23.
Ensign Group (ENSG) Beats on Q2 Earnings, Raises '23 EPS View
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results benefit from improved occupancies, skilled and managed care revenue. Rising expenses acted as a partial offset.
Ensign Group (ENSG) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.75% and 1.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy The Ensign Group (ENSG) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why Ensign Group (ENSG) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
Brookdale (BKD) Reports Occupancy Growth for 20 Straight Months
by Zacks Equity Research
The continuous uptick observed in Brookdale's (BKD) weighted average occupancy level is expected to inflict a favorable impact on its resident fee revenues in the days ahead.
Molina (MOH) to Buy Bright Health's California Medicare Business
by Zacks Equity Research
Molina's (MOH) Brand New Day and Central Health Plan of California buyout complements Molina's Medicaid footprint and aligns with its 2024 Medi-Cal plan.
Ensign Group (ENSG) Up 26% in a Year: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.
UnitedHealth Group (UNH) Expands Home Healthcare Business
by Zacks Equity Research
UnitedHealth Group (UNH) boosts home healthcare presence with the acquisition of Amedisys for $3.3 billion
Zacks.com featured highlights Terex, Caterpillar and Ensign
by Zacks Equity Research
Terex, Caterpillar and Ensign have been highlighted in this Screen of The Week article.
UnitedHealth's (UNH) Optum Rx Makes Patient Care Affordable
by Zacks Equity Research
UnitedHealth Group, Inc's. (UNH) Optum Rx is set to offer three biosimilar alternatives for HUMIRA effective Jul 1, providing affordability in patient care.
3 Stocks Worth a Buy for Solid Earnings Growth in 2H 2023
by Tirthankar Chakraborty
Invest in stocks like Terex (TEX), Caterpillar (CAT) & Ensign Group (ENSG), as of now, for superb earnings growth.
Why Ensign Group (ENSG) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
UnitedHealth's (UNH) Program to Aid Georgia's Diabetic Patients
by Zacks Equity Research
UnitedHealth's (UNH) unit, UnitedHealthcare, extends its community-based program to improve the health conditions of Southwest Georgia's diabetic patients.
Are Investors Undervaluing The Ensign Group (ENSG) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Encompass Health's (EHC) 158th Hospital Opens in Maryland
by Zacks Equity Research
The Rehabilitation Hospital of Bowie is Encompass Health's (EHC) second location in the state of Maryland.
Centene (CNC) to Provide Managed Care for SoonerSelect Program
by Zacks Equity Research
Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.
UnitedHealth Group (UNH) Hikes Quarterly Dividend by 14%
by Zacks Equity Research
UnitedHealth Group's (UNH) recent dividend hike highlights a solid financial position and efforts to sustain its sound capital deployment history.